Related by context. All words. (Click for frequent words.) 78 prostate specific 74 antigen PSA levels 71 Prostate Specific Antigen PSA 70 Prostate specific antigen 70 specific antigen PSA 69 serum PSA 68 prostate specific antigen 68 specific antigen 67 cystatin C 67 #.#ng/ml 66 grade cervical intraepithelial 66 thyroglobulin 66 Prostate Specific Antigen 66 prostate cancer CaP 66 serum prostate 66 CIN2 + 66 chlamydial infection 65 colorectal neoplasia 65 sarcosine 65 PSA prostate 65 tHcy 65 cTnI 65 elevated CRP 65 epithelial ovarian cancer 65 HER2 expression 65 PCA3 scores 65 PSA nadir 65 hs CRP 64 Lp PLA2 64 alanine aminotransferase ALT 64 colorectal adenoma 64 thyroid stimulating hormone 64 prostate cancer PCa 64 cTnT 64 D dimer 64 cardiac troponin T 63 N telopeptide 63 aspartate aminotransferase AST 63 subclinical atherosclerosis 63 testosterone supplementation 63 PCa 63 colorectal cancer CRC 63 pCR 63 clinically localized prostate 63 neoplasia PIN 63 advanced adenomas 63 MSMB 63 fetuin 63 glycosylated hemoglobin HbA1c 63 natriuretic peptide 62 carcinoembryonic antigen 62 serum testosterone 62 intact parathyroid hormone 62 C Reactive Protein 62 B7 H3 62 PCA3 62 lactate dehydrogenase 62 Cervista HPV HR 62 HNSCC 62 advanced adenoma 62 serum calcium 62 nonmelanoma skin cancers 62 platelet reactivity 62 aminotransferases 62 precursor lesions 62 glycated hemoglobin levels 62 hydroxyvitamin D levels 62 lobular carcinoma 62 NMP# 62 MGUS 62 colorectal carcinoma 62 HER2 overexpression 62 clusterin 62 cervical intraepithelial neoplasia 62 elevated LDL cholesterol 62 ovarian carcinoma 62 serous ovarian cancer 62 coronary calcification 62 digital rectal examination 62 anti JCV antibodies 62 HGPIN 61 renal cell carcinomas 61 urine cytology 61 transferrin saturation 61 urate levels 61 mitochondrial toxicity 61 KRAS mutation 61 atypical hyperplasia 61 Ki# 61 ptau 61 serum urate levels 61 cTnT levels 61 skin sterol 61 glycosylated hemoglobin 61 protein excretion 61 #F FDG PET 61 thyroid stimulating hormone TSH 61 lactate dehydrogenase LDH 61 SUVmax 61 Clusterin 61 GSTP1 61 endometrial carcinoma 61 BRCA2 mutation carriers 61 atypical ductal hyperplasia 61 deCODE BreastCancer TM 61 spiral computed tomography 61 Radical prostatectomy 61 differentiated thyroid 61 NT proBNP 61 elevated homocysteine 61 grade gliomas 61 aspartate aminotransferase 61 thyroid nodules 61 CVD mortality 61 follicle stimulating hormone FSH 61 troponin T 61 glycated hemoglobin 61 elevated ALT 61 prognostic indicator 61 RBC folate 61 abdominal adiposity 61 CTAP# Capsules 61 immunochemical fecal occult 61 cervical lesions 61 glycated hemoglobin HbA1c 61 abnormal lipid 61 nonfasting triglycerides 61 prostate ovarian 61 ERCC1 61 advanced neoplasia 61 p# antigen 61 DHEAS 61 adenoma recurrence 60 K ras mutations 60 CIN3 60 PSA velocity 60 creatinine levels 60 biochemical recurrence 60 mammographic density 60 dysglycemia 60 macroalbuminuria 60 albumin excretion 60 androgen deficiency 60 elevated serum creatinine 60 serum thyroglobulin 60 serum ferritin 60 clinically insignificant 60 precancerous cervical lesions 60 serum creatinine levels 60 PSA kinetics 60 metastatic renal cell carcinoma 60 cardiac troponin 60 intima media thickness 60 soluble CD# ligand 60 ASCUS 60 TGFBR1 * 6A 60 Haptoglobin 60 serum potassium 60 hydroxy vitamin D 60 hematopoietic cancers 60 BRCA mutations 60 grade glioma 60 urine NGAL 60 thiopurine 60 lipid abnormalities 60 CaP 60 atypia 60 Inhibin B 60 olaparib 60 serum TSH 60 estrogen progestin therapy 60 Zolinza 60 F FDG PET 60 C reactive protein 60 paricalcitol 60 relapsed MM 60 alanine aminotransferase 60 polyp recurrence 60 basal cell nevus syndrome 60 serum biomarkers 60 serum urate 60 troponins 60 nonsmall cell lung cancer 60 HER2 positive cancers 60 amino acid homocysteine 60 aminotransferase ALT 60 prostate carcinoma 60 PSADT 60 kidney allograft 60 hsCRP 60 serum phosphate 60 Lp PLA 2 60 creatine kinase 60 MGd 60 eosinophil count 60 diabetic kidney 60 dehydroepiandrosterone sulfate 60 postoperative mortality 60 microalbumin 60 PCA3 gene 60 endometrial cancers 60 breast carcinomas 60 adenoma 60 plasma lipid 60 metastatic colorectal 60 cardiac biomarkers 60 HIV HCV coinfected 60 fasting insulin 60 deCODE ProstateCancer TM 60 AST ALT 60 FISH fluorescence 60 obstructive coronary artery 60 trastuzumab Herceptin ® 59 Cervista HPV 59 androgen suppression therapy 59 carotid stenosis 59 subclinical hypothyroidism 59 biochemical relapse 59 atherogenic dyslipidemia 59 microalbuminuria 59 node metastases 59 flavopiridol 59 selenium intake 59 gastric carcinoma 59 tPSA 59 recurrent UTI 59 invasive coronary angiography 59 gefitinib Iressa 59 elevated uric acid 59 cervical carcinoma 59 HER2 positive metastatic breast 59 Cotinine 59 squamous intraepithelial lesions 59 rheumatoid factor 59 carotid IMT 59 serum calcium levels 59 glomerular filtration rate 59 undergoing radical prostatectomy 59 leukemia AML 59 colorectal adenomas 59 BRAF mutation 59 postoperative chemotherapy 59 homocysteine concentrations 59 FeNO 59 non squamous NSCLC 59 EGFR mutation 59 virologic response 59 serum estradiol 59 abnormal cytology 59 glomerular filtration 59 elevated creatinine 59 nonfasting triglyceride levels 59 endometrial hyperplasia 59 intravesical therapy 59 endocrine therapies 59 preoperative PSA 59 R0 resection 59 c reactive protein 59 isoprostane 59 gastric adenocarcinoma 59 neutrophil counts 59 Doxil ® 59 hsCRP levels 59 imatinib Gleevec 59 HOMA IR 59 NGAL 59 EpCAM expression 59 RBP4 59 NMIBC 59 Homocysteine levels 59 detecting colorectal cancer 59 seminoma 59 microvessel density 59 ELISpot 59 invasive lobular 59 urine albumin 59 intensive statin therapy 59 mycophenolate mofetil 59 EUS FNA 59 lymph node metastases 59 imatinib therapy 59 Androgen deprivation therapy 59 genetic polymorphisms 59 intestinal polyps 59 serum cortisol 59 conventional coronary angiography 59 latent tuberculosis infection 59 serum uric acid 59 PARP inhibitor 59 prostate tumor 59 transaminase levels 59 hypogonadal 59 undetectable PSA 59 #ng/ml 59 malondialdehyde 59 inflammatory biomarkers 59 apolipoprotein B 59 antibody titer 59 multivariable analysis 59 Corus CAD 59 anti Mullerian hormone 59 microsatellite instability 59 IDH1 mutation 59 ductal breast cancer 59 serum parathyroid hormone 59 precancer 59 EGFR mutation status 59 Adenomas 59 potentially cancerous polyps 59 coronary artery calcium 59 mesothelin 59 ImmuKnow 59 ovarian lung 59 STRIDE PD 59 peptide BNP 59 Septin9 59 stratifying patients 59 HPV# 59 PSA screening 59 GnRH agonists 59 sDNA 59 fosamprenavir 58 CYT# potent vascular disrupting 58 apolipoprotein A1 58 undergone radical prostatectomy 58 rs# [002] 58 urothelial carcinoma 58 Estradiol 58 serum folate 58 recurrent VTE 58 colorectal neoplasms 58 galiximab 58 immunohistochemical 58 ovarian hormones 58 hyperphenylalaninemia HPA due 58 colorectal cancer 58 serum HBV DNA 58 genetic variants associated 58 tumor hypoxia 58 mRCC 58 albuminuria 58 SCr 58 thromboembolic disease 58 BRCA1 mutations 58 pancreatic adenocarcinoma 58 myeloperoxidase 58 5alpha reductase 58 MammaPrint R 58 colorectal pancreatic 58 F2 isoprostanes 58 serum phosphorous 58 virologic failure 58 metastatic castration resistant 58 adjuvant radiotherapy 58 hereditary hemochromatosis 58 BRAF V#E mutation 58 Hashimoto thyroiditis 58 PlGF 58 MAGE A3 ASCI 58 serum biomarker 58 postoperative pulmonary 58 Telintra 58 univariate analyzes 58 latent tuberculosis TB 58 PHPT 58 serum homocysteine 58 angiotensin receptor blockers ARBs 58 Subgroup analyzes 58 nanomolar 58 invasive ductal 58 CBLC# 58 adiponectin levels 58 neoplasias 58 selenium supplementation 58 E selectin 58 arterial thickening 58 Immunohistochemistry 58 Rectal cancer 58 fluvastatin 58 multivariate Cox 58 Subgroup analysis 58 Prehypertension 58 fasting glucose levels 58 lipid lowering drugs 58 colon tumors 58 eGFR 58 SERMs 58 hypercholesterolaemia 58 KRAS status 58 sensitivity specificity 58 transaminase elevations 58 Viral load 58 elevated triglyceride levels 58 standard chemotherapy regimen 58 FDG PET 58 prostate cancers 58 cetuximab Erbitux 58 risk HPV genotypes 58 ADPKD 58 asymptomatic carotid stenosis 58 cardiotoxicity 58 Septin 9 58 tumor histology 58 curative resection 58 ductal cancer 58 mIU L 58 KRAS mutations 58 beta blocker therapy 58 intravenous bisphosphonates 58 H. pylori eradication 58 galectin 3 58 BRCA mutation 58 plasma homocysteine 58 retrospective cohort 58 hematological parameters 58 procalcitonin 58 LV dysfunction 58 LVNC 58 methylation markers 58 grade squamous intraepithelial 58 axillary lymph nodes 58 colorectal polyp 58 gemcitabine Gemzar 58 prognostic significance 58 serum CRP 58 HBeAg 58 MDRD equation 58 histologic subtype 58 serum vitamin D 58 Coronary artery calcium 58 Homocysteine 58 hip BMD 58 chemoresistance 58 riociguat 58 NAbs 58 albumin protein 58 β blockers 58 serum clusterin levels 58 micronuclei 58 protein albumin 58 CC genotype 58 Epidermal Growth Factor Receptor 58 lung metastasis 58 Recurrence Score 58 lipoprotein 58 FDG PET imaging 58 ApoB 58 NHANES III 58 Cystatin C 58 Epigenomics proprietary 58 maternal serum 58 elevated triglycerides 58 nonalcoholic steatohepatitis NASH 58 serum GGT 58 Faslodex 58 grade cervical dysplasia 58 micrometastasis 58 INCB# [003] 58 EGFR protein 58 thyrotropin levels 58 nuchal translucency 58 SHBG 58 NNRTI resistance 58 SGPT 57 pmol L 57 epithelial tumors 57 cortisol concentrations 57 hydroxyvitamin D 57 NMP# protein 57 EGFR TKI 57 HER2 amplification 57 thyrotropin 57 pertuzumab 57 ng dL 57 carotid intima media 57 DFMO 57 malignant nodules 57 CIN3 + 57 HBsAg 57 NQO1 57 BMS# 57 serum IGF 57 proteinuria 57 coronary stenosis 57 guaiac 57 cerebral microbleeds 57 Hemoglobin A1c 57 urate 57 myocardial ischemia 57 TT genotype 57 invasive carcinomas 57 serum lipid levels 57 serologic 57 HbA1C 57 perioperative morbidity 57 antiangiogenic therapy 57 PCNSL 57 paraprotein 57 XIENCE V PROMUS Stent 57 alpha fetoprotein 57 testicular germ cell 57 serum selenium 57 2 diabetes T2D 57 androgen ablation 57 SLNB 57 Helicobacter pylori infection 57 gestational diabetes mellitus 57 HAAH 57 oestradiol 57 reticulocytes 57 abnormal glucose metabolism 57 pancreatic lung 57 Non inferiority 57 malignant pleural mesothelioma 57 CK MB 57 pheochromocytoma 57 oropharyngeal cancer 57 BRCA2 carriers 57 prognostic markers 57 Adjuvant chemotherapy 57 A3 adenosine receptor 57 bevacizumab Avastin 57 iPTH 57 neoadjuvant therapy 57 benign breast 57 natriuretic peptides 57 histological subtype 57 neoadjuvant chemotherapy 57 blood phenylalanine Phe 57 nutlin 3a 57 telomere lengths 57 endoglin 57 serum triglycerides 57 liver transplant recipients 57 genotypic resistance 57 interleukin IL -# 57 locoregional recurrence 57 hemoglobin A1C 57 teriflunomide 57 Multivariate analysis 57 thromboembolism 57 postmenopausal breast cancer 57 overt hypothyroidism 57 CHD mortality 57 vitro assay 57 PBDE chemicals 57 microalbumin test 57 nodal metastasis 57 BRAF mutations 57 follicular lymphoma FL 57 HbA 1c 57 chronic prostatitis 57 PASI scores 57 aldosterone antagonist 57 Her2/neu 57 bioavailable testosterone 57 colorectal tumors 57 pg ml 57 urinary calcium 57 WT1 57 aminotransferase levels 57 Squamous 57 diuretic hydrochlorothiazide 57 hydroxyvitamin D concentrations 57 atherosclerotic lesions 57 polycystic ovary syndrome PCOS 57 breast carcinoma 57 calculated creatinine clearance 57 density lipoprotein HDL cholesterol 57 serum testosterone levels 57 protease inhibitor PI 57 malignant lesions 57 Getzenberg 57 pretest probability 57 immunochemical 57 dose clopidogrel 57 capecitabine Xeloda 57 ALA PDT 57 systolic dysfunction 57 p#INK#a 57 gallstone disease 57 ADAMTS# 57 Elevated PSA 57 idarubicin 57 mucinous 57 triiodothyronine 57 premenopausal breast cancer 57 neoplasia 57 erlotinib Tarceva ® 57 univariate analysis 57 serum leptin 57 Bucindolol 57 bacterial prostatitis 57 carotid atherosclerosis 57 NSTE ACS 57 nephrogenic 57 hepatocellular carcinomas 57 plasma folate 57 serum albumin 57 thickness IMT 57 univariate 57 8 OHdG 57 pretargeting 57 SNP rs# [001] 57 radical prostatectomy RP 57 multivariate logistic regression 57 transaminases 57 definite stent thrombosis 57 recurrent glioblastoma multiforme 57 Microalbuminuria 57 subclinical hyperthyroidism 57 hemoglobin A1c HbA1c 57 recurrent ovarian cancer 57 elevated LDH 57 cerebrospinal fluid CSF 57 colon rectal 57 coinfected patients 57 hypercholesterolemia 57 #.#mmol L [002] 57 androgenic hormones 57 methylmalonic acid 57 onset diabetes mellitus 57 #F FDG 57 distal colon cancer 57 prostate walnut 57 cyclin E 57 LHRH analogues 57 alpha carotene 57 troponin 57 precancerous cervical 57 premalignant lesions 57 androgen deprivation 57 precancerous tumors 57 monocytic 57 TIMP 1 57 HIV RNA 57 β amyloid 57 contralateral breast 57 ductal carcinomas 57 exhaled nitric oxide 57 cardiovascular mortality 57 situ LCIS 57 Skin sterol 57 prostate cancer 57 Oxidized LDL 57 axillary lymph node 57 medically inoperable 57 GISTs 57 colorectal lung 57 leukaemias 57 recurrent NSCLC 57 sCJD 57 Leitzmann 57 hormone therapy estrogen 57 Vidaza azacitidine 57 nonnucleoside reverse transcriptase inhibitors 57 transthyretin 57 refractory prostate cancer 57 colorectal polyps 57 prognostic indicators 57 myocardial necrosis 57 unresectable tumors 57 PSMA ADC 57 airway responsiveness 57 neoplasia CIN 57 thickness CIMT 57 triglyceride concentrations 57 narcolepsy cataplexy 57 LDL Cholesterol 57 osteopenic 57 Epratuzumab 57 plasma triglycerides 57 HLA DR 57 basal cell carcinoma BCC 57 prostate biopsy 57 Dasatinib 57 urolithiasis 57 Bone density 56 lupus anticoagulant 56 ritonavir boosted 56 carcinoid 56 SHBG levels 56 testicular cancers 56 esophageal squamous cell carcinoma 56 distant metastasis 56 serum IgE 56 warfarin therapy 56 IGFBP 56 taxane therapy 56 cytoreductive surgery 56 lymphocytosis 56 bladder cancers 56 invasive carcinoma 56 transient elastography 56 #beta 56 NATRECOR ® 56 EGFR inhibitors 56 HbF 56 FDG-PET/CT 56 Pemetrexed 56 Hurthle cell 56 metastatic lung cancer 56 gastrointestinal cancers 56 chemosensitivity 56 follicle stimulating hormone 56 BRCA2 mutations 56 esophageal adenocarcinoma 56 dasatinib Sprycel 56 cisplatin resistant 56 biochemical marker 56 oophorectomy 56 SERCA2a 56 sentinel lymph node biopsy 56 mutated BRCA1 56 malignant polyps 56 ErbB2 positive 56 HBeAg negative 56 GRASPA ® 56 pT2 56 liposomal doxorubicin 56 Screening Trial 56 EBV infection 56 erlotinib Tarceva 56 bezafibrate 56 ezetimibe simvastatin 56 undergo prostate biopsy 56 hormone receptor negative 56 antitumor effect 56 TP# mutations 56 Lymph node 56 TRAIL R2 56 PTPN# 56 histopathologic examination 56 underwent surgical resection 56 LDL particle 56 APOL1 56 IgG antibody 56 preserved ejection fraction 56 prostate cancer CRPC 56 Digital Mammographic Imaging 56 overt nephropathy 56 dutasteride 56 IGF IR 56 OGTT 56 penetrance 56 metastatic gastric 56 Leydig cell 56 hyperinsulinemic euglycemic clamp 56 beta1 integrin 56 human chorionic gonadotropin hCG 56 BladderChek 56 trans retinoic acid 56 eplerenone 56 FDG uptake 56 bevacizumab Avastin ® 56 NPM1 56 methylated DNA 56 serum concentrations 56 oncologic outcomes 56 CT coronary angiography 56 Coronary artery calcification 56 TNF blocker therapy 56 thyroxine 56 Folfox 56 Ceplene/IL-2 56 flutamide 56 acute humoral rejection 56 ALB # 56 LY# [003] 56 ovarian pancreatic 56 urinary oxalate 56 Cardiotoxicity 56 taxane chemotherapy 56 Xelox 56 VKORC1 56 cytoreductive nephrectomy 56 CMV infection 56 IV bisphosphonates 56 Immunohistochemical staining 56 oral antidiabetic medication 56 postoperative complication 56 K ras mutation 56 undetectable HBV DNA 56 serum BDNF 56 ABCB1 56 anti HBs 56 inotropic 56 parathyroid 56 plasma renin activity 56 dose atorvastatin 56 hemoglobin A1c 56 hemoglobin A1c levels 56 lymphadenectomy 56 pre eclamptic 56 LTBI 56 p# biomarker 56 decitabine 56 d dimer 56 resistant hormone refractory 56 nonmetastatic 56 statistical significance p 56 hepatic lesions 56 low expressors 56 PROLARIS 56 OPCAB 56 estrogen receptor ER 56 HER-2/neu 56 TNF α 56 EGFR mutations 56 adenomatous polyps 56 immunohistochemical staining 56 APTIVUS r 56 nonmelanoma skin cancer 56 Fasting glucose 56 clinically detectable 56 rosuvastatin Crestor 56 Sentinel node biopsy 56 contralateral breast cancer 56 AGHD 56 castration resistant prostate cancer 56 carotid plaques 56 aneuploidy 56 transvaginal ultrasound 56 flurpiridaz F 56 cardiovascular morbidity 56 liver metastasis 56 PITX2 56 autoantibody levels 56 Cholangiocarcinoma 56 hepatocellular carcinoma 56 transcranial Doppler ultrasound 56 TIMP 56 fulvestrant 56 underwent radical prostatectomy 56 pre menopausal 56 prospectively defined 56 Tr DNA 56 fasting triglycerides 56 neurocognitive function 56 metastatic lesions 56 BENICAR HCT 56 density lipoprotein cholesterol 56 neutrophil count 56 5-FU/LV 56 KRAS oncogene 56 LungAlert TM 56 antioxidant supplementation 56 ixabepilone 56 distant metastases 56 Darapladib 56 XmAb# 56 posttransplant 56 sustained virologic response 56 LRP5 56 IFN beta 56 tuberculin skin testing 56 trastuzumab Herceptin 56 varicocele 56 postmenopausal hormone therapy 56 invasive lobular carcinoma 56 BRAF inhibitor 56 Immunohistochemical analysis 56 A2 Lp PLA2 56 operable breast cancer 56 tibolone 56 highest tertile 56 mercaptopurine 56 total cholesterol LDL 56 adenocarcinomas 56 ovarian breast 56 pediatric malignancies 56 gastrointestinal stromal tumor GIST 56 Tavocept 56 lignan intake 56 QuantiFERON 56 temsirolimus 56 adjuvant radiation 56 logistic regression analyzes 56 androgenetic alopecia 56 BRCA mutation carriers 56 metastatic bladder 56 apo B 56 pleural fluid 56 familial hypercholesterolemia 56 Herceptin trastuzumab 56 abnormal Pap test 56 cytokeratin 56 urinary N telopeptide 56 prostate pancreatic 56 trials RCTs 56 lipid elevations 56 aromatase inhibitors AIs 56 pegylated liposomal doxorubicin 56 peritoneal cancer 56 elevated liver enzymes 56 relapsed ovarian cancer 56 atrasentan 56 intravascular ultrasonography 56 Alkaline Phosphatase 56 ALT normalization 56 lipoprotein Lp 56 D Dimer 56 RRM1 56 telomerase activation 56 FGFR2 56 Menopausal hormone therapy 56 hydroxychloroquine 56 azacytidine 56 mg/m2 dose 56 pg mL 56 Amrubicin 56 endoxifen 56 cabazitaxel 56 alkylating agent 56 renal dysfunction 56 sorafenib Nexavar 56 neuroblastoma tumors 56 PON1 activity 56 Gleevec imatinib mesylate 56 clomipramine 56 AGTR1 56 statin medications 56 PROSTVAC VF 56 hypercalciuria 56 clinicopathological 56 adenoma detection 56 chromosomal aberrations 56 primary hyperparathyroidism 56 nondiabetic patients 56 myelofibrosis polycythemia vera 56 QTc prolongation 56 lipoprotein associated phospholipase 56 rs# [001] 56 aminotransferase 56 Xanafide 56 NSCLC tumors 56 metabolic syndrome MetS 56 VerifyNow 56 APOE genotype 56 serum cholesterol 56 serum aminotransferase levels 56 HBeAg seroconversion 56 nonfasting 56 leukocyte count 56 plasma pharmacokinetics 56 mIU ml 56 sustained virological response 56 elevated troponin 56 serum glucose 56 tumor recurrence 56 peritoneal carcinomatosis 56 Multiple logistic regression 56 OnDose TM 56 dose Iluvien 56 K#N 56 nonmetastatic prostate cancer 56 plasma creatinine 56 Prostate Lung Colorectal 56 DAVANAT 56 TPMT 56 Metastatic Prostate Cancer 56 VEGF expression 56 carboplatin paclitaxel 56 μmol L 56 superficial bladder cancer 56 SLN biopsy 56 renal artery stenosis 56 PGDH 56 calcitriol 56 cytotoxic therapy 55 sentinel nodes 55 H pylori 55 benign proliferative breast 55 colonic polyps 55 microvascular complications 55 lymph node metastasis 55 TNFalpha 55 PLCO trial 55 myeloperoxidase MPO 55 lobular cancer 55 S/GSK# 55 effector function 55 squamous 55 Amniocentesis 55 sweat chloride 55 poor metabolizers 55 catheter angiography 55 Kaplan Meier analysis 55 APTIMA HPV 55 cholesterol LDL C 55 sunitinib 55 dose ritonavir 55 grade prostatic intraepithelial 55 dose ionizing radiation 55 thrombophilia 55 alkaline phosphatase ALP 55 Prostatitis 55 receptor tyrosine kinase inhibitor 55 helical CT